PE55998A1 - Derivados 19-nor-pregneno substituidos - Google Patents
Derivados 19-nor-pregneno substituidosInfo
- Publication number
- PE55998A1 PE55998A1 PE1997000035A PE00003597A PE55998A1 PE 55998 A1 PE55998 A1 PE 55998A1 PE 1997000035 A PE1997000035 A PE 1997000035A PE 00003597 A PE00003597 A PE 00003597A PE 55998 A1 PE55998 A1 PE 55998A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- formula
- alkyl
- compounds
- refer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: "X" ES OXIGENO O UN GRUPO FUNCIONAL HIDROXIIMINO; R1, R2, R3 Y R4 SON HIDROGENO O ALQUILO C1-C6, EN DONDE: SI n ES CERO, DOS DE R1, R2, R3 Y R4 NO SON HIDROGENO, SI n ES UNO, R3 Y R4 NO SON SIMULTANEAMENTE HIDROGENO; R5 ES PREFERENTEMENTE -COR7, EN DONDE R7 ES ALQUILO C1-C6; R6 ES PREFERENTEMENTE HIDROGENO. TAMBIEN SE REFIEREN A LAS COMPOSICIONES QUE COMPRENDEN AL COMPUESTO DE FORMULA (I) COMO PRINCIPIO ACTIVO SOLO, PARA TRATAR LOS TRANSTORNOS GINECOLOGICOS ASOCIADOS CON UN DESEQUILIBRIO ESTROGENO/PROGESTERONA O PARA INHIBIR LAS SECRECIONES GONADOTROPICAS/GONADALES, O EN COMBINACION CON UN ESTEROIDE SEXUAL, COMO ANTICONCEPTIVO, O CON UN ESTROGENO, PARA EL TRATAMIENTO DE REEMPLAZO HORMONAL POST-MENOPAUSICO. ESTOS COMPUESTOS DE FORMULA (I) HAN DESARROLLADO UNA POTENTE ACTIVIDAD PROGESTAGENA SIN PRESENTAR ACTIVIDAD ANDROGENICA RESIDUAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96400146A EP0785212A1 (en) | 1996-01-22 | 1996-01-22 | New 19-nor-pregnene derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
PE55998A1 true PE55998A1 (es) | 1998-10-01 |
Family
ID=8225217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1997000035A PE55998A1 (es) | 1996-01-22 | 1997-01-22 | Derivados 19-nor-pregneno substituidos |
Country Status (36)
Country | Link |
---|---|
US (1) | US6180803B1 (es) |
EP (2) | EP0785212A1 (es) |
JP (2) | JP4368945B2 (es) |
KR (1) | KR100396902B1 (es) |
CN (1) | CN1187366C (es) |
AP (1) | AP1176A (es) |
AR (1) | AR005500A1 (es) |
AT (1) | ATE184015T1 (es) |
BR (1) | BR9707064A (es) |
CA (1) | CA2243504C (es) |
CO (1) | CO4810230A1 (es) |
CZ (1) | CZ292047B6 (es) |
DE (1) | DE69700470T2 (es) |
DZ (1) | DZ2169A1 (es) |
EE (1) | EE03692B1 (es) |
ES (1) | ES2140961T3 (es) |
GR (1) | GR3031954T3 (es) |
HK (1) | HK1018216A1 (es) |
HU (1) | HU221796B1 (es) |
ID (1) | ID15840A (es) |
IL (1) | IL125379A (es) |
IS (1) | IS1902B (es) |
JO (1) | JO1971B1 (es) |
MY (1) | MY116845A (es) |
NO (1) | NO309572B1 (es) |
NZ (1) | NZ330954A (es) |
OA (1) | OA10813A (es) |
PE (1) | PE55998A1 (es) |
PL (1) | PL185608B1 (es) |
RU (1) | RU2166509C2 (es) |
SI (1) | SI0886645T1 (es) |
TN (1) | TNSN97015A1 (es) |
TR (1) | TR199801399T2 (es) |
TW (1) | TW411345B (es) |
WO (1) | WO1997027210A1 (es) |
ZA (1) | ZA97521B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2776191B1 (fr) * | 1998-03-23 | 2002-05-31 | Theramex | Composition hormonale topique a effet systemique |
AR028110A1 (es) * | 2000-06-02 | 2003-04-23 | Astrazeneca Ab | Nuevo proceso |
DE60143360D1 (de) | 2000-08-03 | 2010-12-09 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
KR101288265B1 (ko) * | 2003-09-03 | 2013-07-26 | 미스콘 트레이딩 에스.에이. | 자궁 내막증의 치료 방법 |
MXPA06003316A (es) * | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Formulacion farmaceutica transdermica para minimizar los residuos en la piel. |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
US8067399B2 (en) * | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
CN101426475A (zh) | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9173915B1 (en) * | 2014-10-10 | 2015-11-03 | Peter F. Kador | Antioxidant eye drops |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CN109481450B (zh) * | 2015-09-02 | 2021-07-23 | 盛世泰科生物医药技术(苏州)有限公司 | 一种用于预防和治疗白内障的眼用制剂及其制备方法 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
CN110452279B (zh) * | 2019-05-13 | 2022-04-08 | 株洲千金药业股份有限公司 | 三萜类化合物和其药学上可接受的盐及制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1593524A1 (de) * | 1951-01-28 | 1970-08-13 | Schering Ag | Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden |
DE1087127B (de) * | 1958-12-13 | 1960-08-18 | Schering Ag | Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden |
FR1405214A (fr) * | 1962-06-21 | 1965-07-09 | Rhone Poulenc Sa | Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation |
FR1525916A (fr) * | 1965-11-09 | 1968-05-24 | Schering Ag | Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation |
US3891677A (en) * | 1967-06-06 | 1975-06-24 | Schering Corp | 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones |
US3835160A (en) * | 1967-06-06 | 1974-09-10 | Schering Corp | 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby |
BE757286A (fr) * | 1969-10-10 | 1971-04-09 | Ciba Geigy | Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation |
CH538462A (de) * | 1970-10-07 | 1973-06-30 | Ciba Geigy Ag | Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen |
DE3402330A1 (de) * | 1984-01-20 | 1985-07-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
-
1996
- 1996-01-22 EP EP96400146A patent/EP0785212A1/en not_active Withdrawn
-
1997
- 1997-01-17 PL PL97327998A patent/PL185608B1/pl not_active IP Right Cessation
- 1997-01-17 HU HU9900684A patent/HU221796B1/hu not_active IP Right Cessation
- 1997-01-17 EP EP97902235A patent/EP0886645B1/en not_active Expired - Lifetime
- 1997-01-17 IL IL12537997A patent/IL125379A/xx not_active IP Right Cessation
- 1997-01-17 AP APAP/P/1998/001299A patent/AP1176A/en active
- 1997-01-17 US US09/101,775 patent/US6180803B1/en not_active Expired - Fee Related
- 1997-01-17 CN CNB971918228A patent/CN1187366C/zh not_active Expired - Fee Related
- 1997-01-17 SI SI9730015T patent/SI0886645T1/xx not_active IP Right Cessation
- 1997-01-17 CA CA002243504A patent/CA2243504C/en not_active Expired - Fee Related
- 1997-01-17 AT AT97902235T patent/ATE184015T1/de active
- 1997-01-17 EE EE9800219A patent/EE03692B1/xx not_active IP Right Cessation
- 1997-01-17 ES ES97902235T patent/ES2140961T3/es not_active Expired - Lifetime
- 1997-01-17 BR BR9707064-5A patent/BR9707064A/pt not_active Application Discontinuation
- 1997-01-17 NZ NZ330954A patent/NZ330954A/xx not_active IP Right Cessation
- 1997-01-17 RU RU98115774/04A patent/RU2166509C2/ru not_active IP Right Cessation
- 1997-01-17 WO PCT/EP1997/000357 patent/WO1997027210A1/en active IP Right Grant
- 1997-01-17 JP JP52656697A patent/JP4368945B2/ja not_active Expired - Fee Related
- 1997-01-17 CZ CZ19982307A patent/CZ292047B6/cs not_active IP Right Cessation
- 1997-01-17 KR KR10-1998-0705607A patent/KR100396902B1/ko not_active IP Right Cessation
- 1997-01-17 DE DE69700470T patent/DE69700470T2/de not_active Expired - Lifetime
- 1997-01-17 TR TR1998/01399T patent/TR199801399T2/xx unknown
- 1997-01-18 TW TW086100511A patent/TW411345B/zh not_active IP Right Cessation
- 1997-01-21 AR ARP970100228A patent/AR005500A1/es active IP Right Grant
- 1997-01-21 CO CO97002478A patent/CO4810230A1/es unknown
- 1997-01-21 JO JO19971971A patent/JO1971B1/en active
- 1997-01-21 DZ DZ970014A patent/DZ2169A1/fr active
- 1997-01-21 MY MYPI97000215A patent/MY116845A/en unknown
- 1997-01-21 TN TNTNSN97015A patent/TNSN97015A1/fr unknown
- 1997-01-22 ZA ZA9700521A patent/ZA97521B/xx unknown
- 1997-01-22 PE PE1997000035A patent/PE55998A1/es not_active Application Discontinuation
- 1997-01-22 ID IDP970175A patent/ID15840A/id unknown
-
1998
- 1998-07-21 NO NO983356A patent/NO309572B1/no not_active IP Right Cessation
- 1998-07-21 IS IS4800A patent/IS1902B/is unknown
- 1998-07-22 OA OA9800117A patent/OA10813A/en unknown
-
1999
- 1999-07-29 HK HK99103263A patent/HK1018216A1/xx not_active IP Right Cessation
- 1999-11-25 GR GR990403047T patent/GR3031954T3/el unknown
-
2009
- 2009-02-04 JP JP2009024075A patent/JP2009167188A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE55998A1 (es) | Derivados 19-nor-pregneno substituidos | |
DK1446128T3 (da) | Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling | |
EA199900989A1 (ru) | Нестероидные (гетеро)циклически замещенные ациланилиды, обладающие смешанным гестагенным и андрогенным действием | |
UY27437A1 (es) | Compuestos químicos | |
BR9709427A (pt) | Oxa ácidos e compostos relacionados para tratamento de condições da pele | |
EA200201052A1 (ru) | 8β-ГИДРОКАРБИЛЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ В КАЧЕСТВЕ ЭСТРОГЕНОВ ИЗБИРАТЕЛЬНОГО ДЕЙСТВИЯ | |
ATE245992T1 (de) | Progestagen-freie formulierungen von gnrh und estrogen zur behandlung von benignen gynäkologischen störungen | |
UY27436A1 (es) | Compuestos químicos | |
EP0845985A4 (en) | NON-STEROIDIAN SULFATASE INHIBITOR COMPOUNDS AND METHODS OF USE | |
NO924755L (no) | Metoder og preparater for anvendelse i forbindelse med befruktningsinhibering og i behandling av benigne gynekologiske sykdommer | |
HUP0200714A2 (hu) | Gyógyhatású vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
TR200201509T2 (tr) | Farmasötik olarak aktif benzazol türevleri. | |
PE20060555A1 (es) | Derivados de pirrol-oxindol como moduladores del receptor de progesterona | |
DE60130147D1 (de) | Verwendung oraler formulierungen zur behandlung der weiblichen sexuellen störung | |
HUP0400694A2 (hu) | A rotamáz enzim aktivitásának kis molekulájú inhibitorai, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények | |
MY114394A (en) | Estra-1,3,5 (10)-trien derivatives,process for their preparation and pharmaceutical compositions containing these compounds | |
ATE233724T1 (de) | Cyclohexenon langketten alkohol und diese enthaltendes arzneimittel | |
HUP0002951A2 (hu) | Proteáz inhibitor hatású Disz(amino-metil)-keton-származékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
NO159278C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-alkyl-androsta-1,4-dien-3,17-dioner. | |
GB2380939B (en) | Treatment or prevention of auto-immune diseases | |
TW372969B (en) | Pharmaceutical composition for minimizing bone loss | |
AR007012A1 (es) | Compuestos de 2-fenil-3-benzoil-benzotiofenos, composiciones farmaceuticas que los contienen y el uso de dichos compuestos para el tratamiento del sindrome postmenopausico, inhibicion del cancer estrogenodependiente, entre otras afecciones patologicas | |
ES2164400T3 (es) | Esteroides con actividad anticonceptiva y antiosteoporotica. | |
EA200401544A1 (ru) | 9α-ЗАМЕЩЁННЫЕ ЭСТРАТРИЕНЫ В КАЧЕСТВЕ ЭСТРОГЕНОВ ИЗБИРАТЕЛЬНОГО ДЕЙСТВИЯ | |
DE60201415D1 (de) | Bisarylderivate mit fsh rezeptor modulierender aktivität |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |